Literature DB >> 25183340

Contrast-enhanced MR angiography: does a higher relaxivity MR contrast agent permit a reduction of the dose administered for routine vascular imaging applications?

Xiaoying Xing1, Xiangzhu Zeng, Xuan Li, Qiang Zhao, Miles A Kirchin, Gianpaolo Pirovano, Xiaoying Wang, Yuan Li, Roberto Iezzi, Francesco De Cobelli.   

Abstract

PURPOSE: The authors prospectively compared single dose (0.1 mmol/kg bodyweight) gadobenate dimeglumine with double dose (0.2 mmol/kg bodyweight) gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography (CE-MRA) in patients with suspected or known steno-occlusive disease of the carotid, renal or peripheral vasculature using an intra-individual crossover study design.
MATERIALS AND METHODS: Twenty-eight patients with suspected or known steno-occlusive disease of the carotid (n = 16), renal (n = 5) or peripheral arteries (n = 7) were randomised to receive either 0.1 mmol/kg gadobenate dimeglumine or 0.2 mmol/kg gadopentetate dimeglumine for a first CE-MRA procedure. After 3-5 days all patients underwent a second identical CE-MRA procedure with the other contrast agent. Three blinded readers assessed images for vessel anatomical delineation, disease detection/exclusion, and global preference. Diagnostic performance for detection of ≥51 % stenosis was determined for 20/28 patients who also underwent digital subtraction angiography (DSA). Non-inferiority was assessed using the Wilcoxon signed rank, McNemar and Wald tests. Quantitative (signal-to-noise and contrast-to-noise ratio) enhancement based on 3D maximum intensity projection reconstructions was compared.
RESULTS: No differences were noted for any qualitative parameter. Equivalence was reported for all diagnostic preference end-points. Superiority for gadobenate dimeglumine was reported by all readers for sensitivity for disease detection (80.8-86.5 vs. 75.0-82.7 %). Quantitative enhancement was similar for single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine.
CONCLUSIONS: Under identical examination conditions a single 0.1 mmol/kg body weight dose of gadobenate dimeglumine can fully replace a double 0.2 mmol/kg body weight dose of gadopentetate dimeglumine for routine CE-MRA procedures.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25183340     DOI: 10.1007/s11547-014-0434-8

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  28 in total

1.  Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine.

Authors:  Federica Pediconi; Carlo Catalano; Rossella Occhiato; Fiammetta Venditti; Francesco Fraioli; Alessandro Napoli; Miles A Kirchin; Roberto Passariello
Journal:  Radiology       Date:  2005-08-26       Impact factor: 11.105

2.  Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine.

Authors:  Federica Pediconi; Carlo Catalano; Simona Padula; Antonella Roselli; Valeria Dominelli; Sabrina Cagioli; Miles A Kirchin; Gianpaolo Pirovano; Roberto Passariello
Journal:  AJR Am J Roentgenol       Date:  2008-11       Impact factor: 3.959

3.  Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE Study).

Authors:  Jian Wang; Fuhua Yan; Jianyu Liu; Jianping Lu; Dan Li; Jingyuan Luan; Xiaoying Wang; Yuan Li; Roberto Iezzi; Francesco De Cobelli
Journal:  J Magn Reson Imaging       Date:  2013-01-31       Impact factor: 4.813

4.  Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).

Authors:  Z Seidl; J Vymazal; M Mechl; M Goyal; M Herman; C Colosimo; M Pasowicz; R Yeung; B Paraniak-Gieszczyk; B Yemen; N Anzalone; A Citterio; G Schneider; S Bastianello; J Ruscalleda
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

5.  Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MR imaging (DETECT Trial).

Authors:  Laura Martincich; Matthieu Faivre-Pierret; Christian M Zechmann; Stefano Corcione; Harrie C M van den Bosch; Wei-Jun Peng; Antonella Petrillo; Katja C Siegmann; Johannes T Heverhagen; Pietro Panizza; Hans-Björn Gehl; Felix Diekmann; Federica Pediconi; Lin Ma; Fiona J Gilbert; Francesco Sardanelli; Paolo Belli; Marco Salvatore; Karl-Friedrich Kreitner; Claudia M Weiss; Chiara Zuiani
Journal:  Radiology       Date:  2010-12-16       Impact factor: 11.105

Review 6.  Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.

Authors:  Zhitong Zou; Hong Lei Zhang; Giles H Roditi; Tim Leiner; Walter Kucharczyk; Martin R Prince
Journal:  JACC Cardiovasc Imaging       Date:  2011-11

7.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; James Goya Heaf; Henrik S Thomsen
Journal:  Nephrol Dial Transplant       Date:  2007-05-04       Impact factor: 5.992

8.  Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla.

Authors:  Jörg Pintaske; Petros Martirosian; Hansjörg Graf; Gunter Erb; Klaus-Peter Lodemann; Claus D Claussen; Fritz Schick
Journal:  Invest Radiol       Date:  2006-03       Impact factor: 6.016

9.  Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla.

Authors:  Eva Bueltmann; Gunter Erb; Miles A Kirchin; Uwe Klose; Thomas Naegele
Journal:  Invest Radiol       Date:  2008-10       Impact factor: 6.016

10.  Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.

Authors:  Tara Anne Collidge; Peter Campbell Thomson; Patrick Barry Mark; James Phillip Traynor; Alan George Jardine; Scott Thomas William Morris; Keith Simpson; Giles Hannibal Roditi
Journal:  Radiology       Date:  2007-08-17       Impact factor: 11.105

View more
  1 in total

1.  Children With Intracranial Arachnoid Cysts: Classification and Treatment.

Authors:  Zhen Tan; Yongxin Li; Fengjun Zhu; Dongdong Zang; Cailei Zhao; Cong Li; Dan Tong; Heye Zhang; Qian Chen
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.